Brief: Unity Biotechnology Results From Phase 2 Study Of UBX1325 In Patients With Wet Age-Related Macular Degeneration

Unity Biotechnology

27/03/2023 12:28

March 27 (Reuters) - UNITY Biotechnology Inc  UBX.O :
    * UNITY BIOTECHNOLOGY: RESULTS FROM PHASE 2 ENVISION STUDY
OF
UBX1325 IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION
    * UNITY BIOTECHNOLOGY: UBX1325 MONOTHERAPY DID NOT ACHIEVE
NON-INFERIORITY THROUGH 24 WEEKS DUE
    * UNITY BIOTECHNOLOGY INC -  52% OF UBX1325-TREATED PATIENTS
DID
NOT REQUIRE ANTI-VEGF TREATMENT THROUGH 24 WEEKS
    * UNITY BIOTECHNOLOGY INC -  TO SHARE 48-WEEK BEHOLD DME
DATA IN
APRIL AND INTENDS TO INITIATE PHASE 2B STUDY IN DME IN SECOND
HALF OF 2023


Further company coverage:  UBX.O 

 ((Reuters.Briefs@thomsonreuters.com;))